Keyphrases
Anthracyclines
12%
Bendamustine
25%
Better Prognosis
25%
Bi-national
50%
Clinical Practice
25%
Computed Tomography-guided
25%
Confidence Interval
25%
Cumulative Incidence
12%
Cytarabine
10%
Disease Outcome
6%
Disease Progression
22%
Disease-specific Survival
10%
Early Progression
18%
Excess Mortality
16%
Female Patients
25%
Finland
6%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
25%
Follicular Lymphoma
75%
Follow-up Interval
10%
Frontline Treatment
12%
Hazard Ratio
18%
High-dose Cytarabine
18%
Histologic Transformation
20%
Lymphoma
16%
Lymphoma Patients
10%
Male Sex
6%
Mantle Cell Lymphoma
50%
Multicenter Cohort
6%
Overall Survival
10%
Patient Demographics
8%
Patient Survival
25%
POD24
9%
Primary Central Nervous System Lymphoma (PCNSL)
25%
Prognostic Value
6%
Rare Type
8%
Re-biopsy
25%
Relapse Detection
15%
Remission
25%
Retrospective Analysis
50%
Rituximab
8%
Rituximab Era
29%
Second-line Treatment
25%
Sex Differences
6%
SUVmax
15%
Systematic Follow-up
10%
Trajectory Basis
8%
Treatment Efficacy
6%
Treatment Facilities
8%
Treatment Patterns
6%
Treatment Strategy
6%
Medicine and Dentistry
Anthracycline
12%
Autologous Stem Cell Transplantation
20%
B-Cell Lymphoma
12%
Bendamustine
25%
Biopsy Technique
35%
Chemoimmunotherapy
16%
Cumulative Incidence
12%
Cytarabine
29%
Diagnosis
10%
Disease Exacerbation
6%
Disease Specific Survival
6%
Diseases
52%
Drug Megadose
18%
Fluorodeoxyglucose
25%
Follicular Lymphoma
100%
Hazard Ratio
18%
Health Care Cost
16%
Lifespan
25%
Mantle Cell Lymphoma
75%
Mortality
20%
Overall Survival
27%
Patient Population
8%
Patient-Data
6%
Personalized Medicine
8%
Positron Emission Tomography-Computed Tomography
50%
Primary Central Nervous System Lymphoma
50%
Prognostic Factor
6%
Progression Free Survival
16%
Retrospective Study
5%
Rituximab
33%
Sex Difference
6%
Standardized Uptake Value
5%
Survival Rate
8%
Targeted Therapy
8%
Transplantation
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anthracycline
12%
B Cell Lymphoma
12%
Bendamustine
25%
Cytarabine
29%
Disease Specific Survival
6%
Diseases
37%
Follicular Lymphoma
50%
Mantle Cell Lymphoma
75%
Mortality
20%
Overall Survival
22%
Primary Central Nervous System Lymphoma
25%
Progression Free Survival
6%
Remission
25%
Rituximab
33%
Survival Rate
8%
